ACAD
31.936
+0.496
+1.5782%
AEMD
1.517
+0.097
+6.8380%
APRI
1.5
+0.02
+1.35%
ARNA
21.02
0.00
0.00%
ATEC
1.916
-0.004
-0.208%
CNAT
5.16
-0.02
-0.39%
CRXM
0.172
0.00
0.00%
CYTX
0.318
-0.003
-0.837074%
DXCM
75.492
-0.418
-0.5503%
GNMK
9.385
-0.055
-0.583%
HALO
12.07
-0.03
-0.25%
ILMN
193.41
-1.35
-0.69%
INNV
0.115
-0.002
-1.709%
INO
5.575
+0.015
+0.270%
ISCO
1.2
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
127.51
-0.46
-0.36%
LPTN
2.93
-2.93
-100.00%
MBVX
0.47
-0.04
-7.7843%
MEIP
2.55
-0.03
-1.16%
MNOV
5.148
+0.098
+1.9327%
MRTX
5.05
-0.25
-4.72%
MSTX
0.13
-0.01
-5.28%
NBIX
52.11
-0.55
-1.04%
NUVA
63.71
-0.99
-1.53%
ONCS
0.924
-0.016
-1.702%
ONVO
1.889
-0.061
-3.128%
OREX
2.337
-0.003
-0.1154%
OTIC
20.275
-0.075
-0.369%
QDEL
32.97
-0.51
-1.52%
RCPT
231.96
0.00
0.00%
RGLS
0.91
+0.05
+5.8605%
RMD
74.035
-0.515
-0.691%
SCIE
0
0.00
0.00%
SPHS
1.9
+0.01
+0.53%
SRNE
1.675
-0.025
-1.471%
TROV
0.838
-0.012
-1.388942%
VICL
2.38
+0.01
+0.42%
VOLC
18
0.00
0.00%
ZGNX
12.75
+0.3
+2.41%
ACAD
31.936
+0.496
+1.5782%
AEMD
1.517
+0.097
+6.8380%
APRI
1.5
+0.02
+1.35%
ARNA
21.02
0.00
0.00%
ATEC
1.916
-0.004
-0.208%
CNAT
5.16
-0.02
-0.39%
CRXM
0.172
0.00
0.00%
CYTX
0.318
-0.003
-0.837074%
DXCM
75.492
-0.418
-0.5503%
GNMK
9.385
-0.055
-0.583%
HALO
12.07
-0.03
-0.25%
ILMN
193.41
-1.35
-0.69%
INNV
0.115
-0.002
-1.709%
INO
5.575
+0.015
+0.270%
ISCO
1.2
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
127.51
-0.46
-0.36%
LPTN
2.93
-2.93
-100.00%
MBVX
0.47
-0.04
-7.7843%
MEIP
2.55
-0.03
-1.16%
MNOV
5.148
+0.098
+1.9327%
MRTX
5.05
-0.25
-4.72%
MSTX
0.13
-0.01
-5.28%
NBIX
52.11
-0.55
-1.04%
NUVA
63.71
-0.99
-1.53%
ONCS
0.924
-0.016
-1.702%
ONVO
1.889
-0.061
-3.128%
OREX
2.337
-0.003
-0.1154%
OTIC
20.275
-0.075
-0.369%
QDEL
32.97
-0.51
-1.52%
RCPT
231.96
0.00
0.00%
RGLS
0.91
+0.05
+5.8605%
RMD
74.035
-0.515
-0.691%
SCIE
0
0.00
0.00%
SPHS
1.9
+0.01
+0.53%
SRNE
1.675
-0.025
-1.471%
TROV
0.838
-0.012
-1.388942%
VICL
2.38
+0.01
+0.42%
VOLC
18
0.00
0.00%
ZGNX
12.75
+0.3
+2.41%
Home » Archive by Category

Xconomy

CA Stem Cell Agency Chief Randy Mills to Leave After Three Years

May 2, 2017 – 11:58 am

[Updated 5/2/17, 7:30 p.m. ET. See below.] The head of California’s stem-cell agency is stepping down after three years on the job. C. Randall Mills, known as Randy, is leaving the agency to…

[[Click headline to continue reading.]]

Epic Sciences Advances Diagnostic for Late-Stage Prostate Cancer

April 30, 2017 – 8:44 pm

When San Diego’s Epic Sciences raised $30 million almost three years ago, CEO Murali Prahalad told me he saw a big opportunity to use the company’s technology as a diagnostic test to assess how well…

[[Click headline to continue reading.]]

Bio Roundup: Trumpcare Flails, Spinraza Sales, Batten OK & More

April 28, 2017 – 2:30 am

To judge the first 100 days of a new administration is, as many pundits have pointed out, an odd vestige of history, more convenient than significant. Which is why we’ll start this week’s…

[[Click headline to continue reading.]]

Gottlieb’s FDA Nomination Gets Committee Nod, Advances to Senate

April 27, 2017 – 7:53 am

Scott Gottlieb’s nomination to the top post of the FDA is on its way to the full U.S. Senate. The Senate Health, Education, Labor & Pensions Committee voted 14-9 on Thursday to approve Gottlieb’s…

[[Click headline to continue reading.]]

Will New Data Open “Bottlenecks” For Biogen’s Pricey Spine Drug?

April 26, 2017 – 9:30 am

Four months after its drug nusinersen (Spinraza) became the first ever approved to treat the rare genetic disease spinal muscular atrophy, Biogen (NASDAQ: BIIB) released study results Tuesday that…

[[Click headline to continue reading.]]

Forge Therapeutics Raises $15M to Take on Drug-Resistant Superbugs

April 25, 2017 – 11:06 am

One reason that drug-resistant “superbugs” are a growing healthcare problem is the hardiness of gram-negative bacteria, a type of bacteria whose characteristics render many antibiotics ineffective….

[[Click headline to continue reading.]]

While You Were Sleeping: ResMed Builds an Empire in the Cloud

April 25, 2017 – 5:00 am

Over the past 28 years or so, ResMed (NYSE: RMD) has built an empire around its respiratory devices for managing sleep apnea and other forms of “sleep-disordered breathing.” In the fiscal year that…

[[Click headline to continue reading.]]

Becton Dickinson Aims Beyond Diabetes with $24B Bard Deal

April 23, 2017 – 9:27 pm

In a medical technology merger with implications for the healthcare sector in the United States and beyond, Becton Dickinson is acquiring C.R. Bard for $24 billion to tap into the growing markets for…

[[Click headline to continue reading.]]

Bio Roundup: Spinraza Woes, Science March, Baseline Launch & More

April 21, 2017 – 3:15 am

Rumblings of a new Obamacare replacement surfaced this week, while scientists and their supporters prepared for Saturday’s—a.k.a. Earth Day’s—nationwide Marches for Science….

[[Click headline to continue reading.]]

Bio Roundup: Spinraza Woes, Science March, Baseline Launch & More

April 21, 2017 – 3:15 am

Rumblings of a new Obamacare replacement surfaced this week, while scientists and their supporters prepared for Saturday’s—a.k.a. Earth Day’s—nationwide Marches for Science….

[[Click headline to continue reading.]]